 |
 Classify cancer specimens across 30 cancer genes in real time to provide a complete pharmacogenomic profile.
|
 |
- Screen for up to 380 somatic mutations across 30 oncogenes with as little as 500 nanograms of DNA from FFPE or fresh frozen tissue.
- Multiplex panels include all major MAPK and PI3K pathway oncology targets.
- Performed in collaboration with the leading laboratory in mass spectrometry based sequencing with over 1110 tumor samples tested.
MolecularMD PGx Profiler™ Service offers rapid, sensitive detection of up to 380 known somatic mutations across 30 genes involved in cell growth signaling (see Tables for complete listing). Using as little as 500 nanograms of DNA per sample, a complete oncogenic profile can be generated across hundreds of specimens in days instead of months. Two separate panels are offered tailored to somatic mutations in either solid or hematologic tumors.
This powerful service is ideal for screening and cataloging specimens for predictive mutations linked to response or resistance to targeted cancer therapies. Entire libraries of tumor specimen subtypes can be profiled to support biomarker assay development efforts and early phase clinical research programs.
Panel Profiles **
* This service is intended for investigational use only. Not for use in clinical diagnostic procedures.
** Specific mutations provided upon request.
Literature References
THOMAS, R. K., ET AL. High-throughput oncogene mutation profiling in human cancer. Nat Genet 39(3): 347-51.
MACCONAILL LE, CAMPBELL CD, KEHOE SM, BASS AJ, HATTON C, ET AL. (2009) Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples. PLoS ONE 4(11): e7887. doi:10.1371/journal.pone.0007887
Refer to the PGx Profiler.pdf for description and test specifications.